Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q3 2023 · 10-Q
Revenue$9.28M$9.28M−51.2% vs Q3 2022 Net Income-$29.26M-$29.26MN/M vs Q3 2022 EPS Diluted-$0.41-$0.41N/M vs Q3 2022 Operating Income-$31,577,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$24,641,000N/M Margins · derivedOperating margin-340.2%−230.4 pt vs Q3 2022
Net margin-315.2%−210.3 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 6, 2023 · 37 d after period end